BBIO Stock Analysis: BridgeBio Pharma | NASDAQ

Cardiac Amyloidosis, Molybdenum Cofactor, Achondroplasia, Hypoparathyroidism

Total Rating 22

Safety 29

Buy Signal -0.70

Biotechnology
Industry Rotation: -9.9

Market Cap: 13.0B
Avg Turnover: 185M

Risk 3d forecast

Volatility50.9%

VaR 5^th Pctl8.15%

VaR vs Median-2.73%

Reward TTM

Sharpe Ratio0.60

Rel. Str. IBD25

Rel. Str. Peer Group34.8 pctl

Character TTM

Beta1.026

Beta Downside0.747

Hurst Exponent0.341

Choppyness32.6%

Drawdowns 3y

Max DD49.08%

CAGR/Max DD0.84

CAGR/Mean DD2.17

EPS (Earnings per Share)

Last SUE: -0.84
Qual. Beats: -3

Revenue

Rev. CAGR: 265.54%
Rev. Trend: 81.7%

Last SUE: 0.72
Qual. Beats: 0

Warnings

Negative Equity With Losses

Interest Coverage Ratio Critical

Altman Z'' In Financial Distress Zone

Below Avwap Earnings

Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 7.2 years of data

Jan -12.7% 17

Feb +0.4% 15

Mar -0.3% 0

Apr -12.6% 43

May -3.5% 32

Jun +6.3% 25

Jul +4.6% 30

Aug +3.6% 9

Sep -4.8% 22

Oct +4.7% 21

Nov +5.3% 17

Dec +1.3% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: BBIO BridgeBio Pharma

BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a U.S.-based biopharmaceutical company headquartered in Palo Alto, California, founded in 2015. The company focuses on discovering, developing, and commercializing medicines for patients with genetic diseases, with a pipeline spanning multiple therapeutic modalities including small molecules, gene therapy, and biologics.

BridgeBio markets Attruby, an oral TTR stabilizer approved for transthyretin amyloid cardiomyopathy (ATTR-CM), and NULIBRY (Fosdenopterin) for molybdenum cofactor deficiency, a rare metabolic disorder. The companys late-stage pipeline includes low-dose infigratinib (Phase 3) for achondroplasia, Encaleret (Phase 3) for hypocalcemia disorders, BBP-418 (Phase 3) for limb-girdle muscular dystrophy type 2I (LGMD2I), and BBP-812, an AAV-based gene therapy for Canavan disease.

BridgeBio pursues licensing and collaboration agreements with major pharmaceutical partners including Bayer, Alexion, Stanford University, and Novartis, a common strategy among biotechnology companies to share development risk and accelerate commercialization. The company operates within the GICS Biotechnology sub-industry and completed its IPO in June 2019, reflecting the capital-intensive nature of genetic disease drug development, which often requires extended R&D timelines before products reach market.

Headlines to Watch Out For

Attruby launch drives early commercial revenue growth
Phase 3 readouts for infigratinib and encaleret near
High cash burn requires continued capital raises
Competition in ATTR-CM market from Pfizers tafamidis
Pipeline expansion through licensing deals with Bayer and Novartis
Regulatory approvals and label expansions for NULIBRY and Attruby

Piotroski VR-10 (Strict) 2.0

Net Income: -696.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.36 > 0.02 and ΔFCF/TA 25.66 > 1.0
NWC/Revenue: 28.40% < 20% (prev 312.3%; Δ -283.9% < -1%)
CFO/TA -0.36 > 3% & CFO -434.4m > Net Income -696.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.23 > 1.5 & < 3
Outstanding Shares: last quarter (195.8m) vs 12m ago 2.77% < -2%
Gross Margin: 93.35% > 18% (prev 96.19%; Δ -2.85% > 0.5%)
Asset Turnover: 62.07% > 50% (prev 21.83%; Δ 40.24% > 0%)
Interest Coverage Ratio: -6.86 > 6 (EBIT TTM -616.3m / Interest Expense TTM 89.8m)

Altman Z'' -14.30

A: 0.17 (Total Current Assets 1.09b - Total Current Liabilities 890.6m) / Total Assets 1.22b
B: -3.40 (Retained Earnings -4.14b / Total Assets 1.22b)
C: -0.54 (EBIT TTM -616.3m / Avg Total Assets 1.15b)
D: -0.68 (Book Value of Equity -2.52b / Total Liabilities 3.72b)
Altman-Z'' = -14.30 = D

Beneish M -1.74

DSRI: 1.09 (Receivables 254.5m/76.9m, Revenue 713.1m/235.8m)
GMI: 1.03 (GM 96.19% / 93.35%)
AQI: 0.58 (AQ_t 0.08 / AQ_t-1 0.14)
SGI: 3.02 (Revenue 713.1m / 235.8m)
TATA: -0.22 (NI -696.2m - CFO -434.4m) / TA 1.22b)
Beneish M = -1.74 (Cap -4..+1) = CCC

What is the price of BBIO shares?

As of October 20, 2026, the stock is trading at USD 67.94 with a total of 2,292,298 shares traded. Over the past week, the price has changed by +3.33%, over one month by +2.04%, over three months by -15.87% and over the past year by +20.77%.

Current recommended Stop Loss: 61.70 (which is 9.2% or 2.6 ATR below the current price).

Is BBIO a buy, sell or hold?

BridgeBio Pharma has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy BBIO.

StrongBuy: 15
Buy: 6
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the BBIO price?

Analysts Target Price	108.3	59.4%

BridgeBio Pharma (BBIO) - Fundamental Data Overview as of 18 October 2026

Market Cap USD = 13.0b (13.0b USD * 1.0 USD.USD)
P/S = 18.2013
P/B = 123.6828
Revenue TTM = 713.1m USD
EBIT TTM = -616.3m USD
EBITDA TTM = -611.3m USD
Long Term Debt = 1.93b USD (from longTermDebt, last quarter)
Short Term Debt = 551.3m USD (from shortTermDebt, last quarter)
Debt = 2.51b USD (from shortLongTermDebtTotal, last quarter) + Leases 18.3m
Net Debt = 1.79b USD (calculated: Debt 2.51b - CCE 720.2m)
Enterprise Value = 14.8b USD (13.0b + Debt 2.51b - CCE 720.2m)
Interest Coverage Ratio = -6.86 (Ebit TTM -616.3m / Interest Expense TTM 89.8m)
EV/FCF = -33.58x (Enterprise Value 14.8b / FCF TTM -439.9m)
FCF Yield = -2.98% (FCF TTM -439.9m / Enterprise Value 14.8b)
FCF Margin = -61.69% (FCF TTM -439.9m / Revenue TTM 713.1m)
Net Margin = -97.64% (Net Income TTM -696.2m / Revenue TTM 713.1m)
Gross Margin = 93.35% ((Revenue TTM 713.1m - Cost of Revenue TTM 47.5m) / Revenue TTM)
Gross Margin QoQ = 93.83% (prev 94.64%)
Tobins Q-Ratio = 12.13 (Enterprise Value 14.8b / Total Assets 1.22b)
Interest Expense / Debt = 3.58% (Interest Expense 89.8m / Debt 2.51b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -486.9m (EBIT -616.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.23 (Total Current Assets 1.09b / Total Current Liabilities 890.6m)
Debt / Equity = -1.00 (negative equity) (Debt 2.51b / totalStockholderEquity, last quarter -2.52b)
Debt / EBITDA = -2.93 (negative EBITDA) (Net Debt 1.79b / EBITDA -611.3m)
Debt / FCF = -4.07 (negative FCF - burning cash) (Net Debt 1.79b / FCF TTM -439.9m)
Total Stockholder Equity = -2.20b (last 4 quarters mean from totalStockholderEquity)
RoA = -60.61% (Net Income -696.2m / Total Assets 1.22b)
RoE = 31.67% (negative equity) (Net Income TTM -696.2m / Total Stockholder Equity -2.20b)
RoCE = 227.5% (negative capital employed) (EBIT -616.3m / Capital Employed (Equity -2.20b + L.T.Debt 1.93b))
RoIC = -57.81% (negative operating profit) (NOPAT -486.9m / Invested Capital 842.3m)
WACC = 8.07% (E(13.0b)/V(15.5b) * Re(9.09%) + D(2.51b)/V(15.5b) * Rd(3.58%) * (1-Tc(0.21)))
Discount Rate = 9.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 88.55 | Cagr: 4.14%
[DCF] Fair Price = unknown (Cash Flow -439.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.84 | # QB: -3
Revenue Correlation: 81.65 | Revenue CAGR: 265.5% | SUE: 0.72 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.58 | Chg30d=+8.40% | Revisions=+25% | Analysts=7
EPS current Year (2026-12-31): EPS=-2.60 | Chg30d=-0.58% | Revisions=-73% | GrowthEPS=+31.3% | GrowthRev=+106.0%
EPS next Year (2027-12-31): EPS=-0.26 | Chg30d=N/A | Revisions=+25% | GrowthEPS=+90.2% | GrowthRev=+64.0%
[Analyst] Revisions Ratio: -46% (up=2, down=8)